FDA and DEA Shift Medical Cannabis Products from Schedule I to Schedule III
What happened
On April 23, 2026, Acting Attorney General Todd Blanche announced that FDA-approved and state-licensed medical marijuana products are immediately shifted from Schedule I to Schedule III, a less restrictive federal regulatory regime. This action followed a December 18 executive order signed by President Trump to speed up medical marijuana and CBD research.
From eurasiareview.com
Why it matters
The regulatory shift ends a decades-long federal claim that cannabis had no accepted medical use. The change moves products into a less restrictive federal classification, impacting the regulatory environment for medical cannabis and CBD products.
From eurasiareview.com
Who's involved
- FDARegulatory agency that implemented the shift for FDA-approved products
- Drug Enforcement AdministrationUnited States federal law enforcement agency that coordinates substance regulation with the FDA
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- FDASpeculative
The FDA might see changes in the costs and scope of its regulatory oversight following the mandated shift of products to Schedule III
Keep exploring
The entities involved
- FDA
-
Drug Enforcement Administration
United States federal law enforcement agency
Related events
- An Executive Order is intended to fast-track marijuana rescheduling, impacting DEA efforts in the Canadian market.
- Ohio and Pennsylvania regulate cannabis and kratom while the FDA advances government-funded clinical trials for ibogaine research.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.
- The Trump administration is implementing new border rules and regulatory changes regarding prescription drug shipments from Canada.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.